ANI Pharmaceuticals
ANIP
123 hedge funds and large institutions have $402M invested in ANI Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 56 increasing their positions, 33 reducing their positions, and 24 closing their positions.
201% more call options, than puts
Call options by funds: $16.9M | Put options by funds: $5.64M
70% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 33
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2% less funds holding
Funds holding: 126 → 123 (-3)
7% less capital invested
Capital invested by funds: $434M → $402M (-$32.1M)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
Top Buyers
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$7.44M |
| 2 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
+$4.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$3.31M |
| 4 |
TAM
Third Avenue Management
New York
|
+$3.08M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.69M |
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$12.5M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$11.5M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
-$9.66M |
| 4 |
Millennium Management
New York
|
-$5.64M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$4.1M |
ANIP Hedge Fund Activity: Q2 2015 in Review
123 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2015, worth a combined $402M — down 7.4% from $434M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ANIP and 21 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 56 added.
The largest buyer was Healthcare Value Capital, opening a new position worth an estimated $7.44M. The largest seller was Invesco, cutting an estimated $12.5M.
- 123 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2015, down from 126 in Q1 2015.
- Funds reported $402M of ANI Pharmaceuticals stock for Q2 2015, down 7.4% quarter-over-quarter.
- 21 funds opened new ANI Pharmaceuticals positions in Q2 2015 and 24 closed out, a net change of -3 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2015 was Healthcare Value Capital, an estimated $7.44M added.
- The largest ANI Pharmaceuticals seller in Q2 2015 was Invesco, an estimated $12.5M sold.
Based on aggregated 13F filings for Q2 2015.